Business
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. JNJ‑4804 is a novel co‑antibody therapy that blocks the complementary interleukin‑23 (IL‑23) and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of c
About this update from Johnson & Johnson
[{"type":"image","alt":"Royalty Pharma plc","displaySize":"","headline":null,"caption":"Royalty Pharma plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":19,"url":"https://media.zenfs.com/en/globenewswire.com/cfd389aedb614eb79e7cc5d41fbda9e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xNwcgeCTTcyJCz7Bux99iw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3/https://media.zenfs.com/en/globenewswire.com/cfd389aedb614eb79e7cc5d41fbda9e7","width":300,"height":19}},"lazy":false},{"type":"text","content":"NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.","length":317,"tagName":"p"},{"type":"text","content":"JNJ‑4804 is a novel co‑antibody therapy that blocks the complementary interleukin‑23 (IL‑23) and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of chronic immune‑mediated diseases.","length":222,"tagName":"p"},{"type":"text","content":"“We are delighted to collaborate with Johnson & Johnson on the clinical development of JNJ-4804,” said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. “Royalty Pharma has a strong track record of investing in immunology, beginning with early disease-modifying biologics including TNF inhibitors. Johnson & Johnson is a recognized leader in immunology and we believe JNJ-4804 holds substantial promise for patients with chronic immune-mediated diseases. We see this as an exciting opportunity that builds on our commitment to partnering with global biopharma companies.”","length":615,"tagName":"p"},{"type":"text","content":"Advisors","length":8,"tagName":"p"},{"type":"text","content":"Goodwin Procter LLP acted as legal advisors to Royalty Pharma.","length":62,"tagName":"p"},{"type":"text","content":"About Royalty Pharma plc","length":24,"tagName":"p"},{"type":"text","content":"Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap...